The mission and vision of the ACRF Image X Institute is to create, share and apply scientific knowledge to improve human health. We focus on developing and improving anatomic and physiologic cancer imaging methods and integrating these innovations into adaptive medical therapeutic systems, particularly radiation therapy.

A critical step in applying our technology is the translation of our technology through clinical trials, for which we sometimes partner with external companies, including start-ups from our laboratory (see ownership sections below for further details). Although there is generally no financial interest in the outcome of the clinical trials, they are a key step in bringing these technologies to the clinics and to the market.

If the technology is successfully commercialised, the ACRF Image X Institute members and the University of Sydney may hold patents and other intellectual property and may benefit financially from commercialisation of the technology.

ACRF Image X Institute members work with the University to identify and best manage these conflicts.

Some members of the institute are engaged in activities through not-for-profit professional organisations. These activities are those normally expected of academics and are not detailed here.

Professor Paul Keall

Patents
Inventor on patents and patent applications
Inventor on granted US patents
Inventor on US patent applications

Note that some patent filings may not yet be publicly available

Licenses

Leo Cancer Care has been assigned a linear accelerator patent.

Opus Medical has licensed an audiovisual biofeedback patent.

Leo Cancer Care has licensed and been assigned image-guided radiotherapy methods.

Standard Imaging has licensed a motion platform design from Virginia Commonwealth University.

Varian has licensed kV, MV and respiratory monitoring-based image-guided radiotherapy methods from Stanford University.

Research Agreements

Varian, Co-Investigator (Principal Investigator Jeremy Booth) for equipment and support for MLC tracking and KIM.

Siemens (Principal Investigator with Ricky O’Brien) on four-dimensional imaging research.

Varian, Principal Investigator, for MRI treatment planning research.

Ownership

Founder, 20% shareholder and director of Opus Medical Pty Ltd, a company advancing the Breathe Well audiovisual biofeedback device.

Founder, 50% shareholder and director of SeeTreat Pty Ltd, a company that is advancing MRI-guided cancer radiotherapy.

 

Associate Professor Ricky O’Brien

Research Agreements

Siemens (Principal Investigator with Paul Keall) on four-dimensional imaging research.

Ownership

Founder, 5% shareholder and hardware and software developer for Opus Medical Pty Ltd, a company advancing the Breathe Well audiovisual biofeedback device.

 

Kuldeep Makhija

Ownership

Founder, 5% shareholder, hardware and software developer for Opus Medical Pty Ltd, a company advancing the Breathe Well audiovisual biofeedback device.